Open an account

Axonics

AXNX · NASDAQ

$0.429−$0.0611 (−12.47%)TodayMarket closed ·
Prev close $0.4901

About AXNX

Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.

Employees
797
Headquarters
Irvine, California
Listed
Oct 31, 2018
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
axonics.com

AXNX key statistics

Market cap
6.35M
Price-earnings ratio
—
Dividend yield
—
Average volume
1.32M
Volume
240.69K
Open price
$0.439
High today
$0.503
Low today
$0.4053
52 Week high
$73.50
52 Week low
$0.4564

Axonics (AXNX) at a glance

Axonics (AXNX) last traded at $0.429, with a market cap of 6.35M.

Today the stock has traded between $0.4053 and $0.503. The current price is 5.8% above the day's low and 14.7% below its high.

Volume so far is 240.69K shares, below the average of 1.32M shares a day.

Over the past year Axonics has ranged from $0.4564 to $73.50, and now sits 0% of the way up that range.

Axonics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY24 it reported $0.00 per share against an estimate of $0.1355.

AXNX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 147.7% on average.

  1. Q4 FY22: reported $0.01 per share against an estimate of -$0.2465
  2. Q1 FY23: reported -$0.19 per share against an estimate of -$0.2931
  3. Q2 FY23: reported $0.16 per share against an estimate of -$0.1159
  4. Q3 FY23: reported $0.08 per share against an estimate of -$0.0561
  5. Q4 FY23: reported $0.13 per share against an estimate of $0.0594
  6. Q1 FY24: reported -$0.27 per share against an estimate of -$0.0857
  7. Q2 FY24: reported $0.13 per share against an estimate of $0.1313
  8. Q3 FY24: reported $0.00 per share against an estimate of $0.1355

AXNX news

  • 12 Industrials Stocks Moving In Thursday's Intraday Session

  • Press releaseBusiness Wire

    CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors

  • Press releasePRNewswire

    Boston Scientific Closes Acquisition of Axonics, Inc.

  • Press releaseBusiness Wire

    Axonics Reports Third Quarter 2024 Financial Results

  • Press releaseBusiness Wire

    Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

  • Press releaseBusiness Wire

    Axonics Prevails in Patent Infringement Lawsuit with Medtronic

  • Press releaseBusiness Wire

    Axonics Reports Second Quarter 2024 Financial Results

  • Press releaseBusiness Wire

    Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

Similar companies

Companies in the same industry as Axonics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.